BRIEF published on 04/03/2024 at 14:05, 1 year 8 months ago Clairvoyant Therapeutics Advances Psilocybin Clinical Trial for Alcohol Use Disorder Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder Regulatory Pathway
PRESS RELEASE published on 04/03/2024 at 14:00, 1 year 8 months ago Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization Clairvoyant Therapeutics aims to commercialize psilocybin treatment for alcohol use disorder by 2025. Company's trial progressing well, expecting results in 2024 & financing round underway Commercialization Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder
PRESS RELEASE published on 11/29/2023 at 13:00, 2 years ago Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder
PRESS RELEASE published on 03/20/2023 at 12:00, 2 years 8 months ago First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder
Published on 12/05/2025 at 02:35, 3 hours 28 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 3 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 58 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 3 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 32 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 12 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 37 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 47 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 52 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 3 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 18 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 18 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 2 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
